<?xml version="1.0" encoding="UTF-8"?>
<ref id="B33-pharmaceuticals-13-00233">
 <label>33.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Sobke</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Makarewicz</surname>
    <given-names>O.</given-names>
   </name>
   <name>
    <surname>Baier</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Bar</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Pfister</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Gatermann</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Pletz</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Forstner</surname>
    <given-names>C.</given-names>
   </name>
  </person-group>
  <article-title>Empirical treatment of lower urinary tract infections in the face of spreading multidrug resistance: In vitro study on the effectiveness of nitroxoline</article-title>
  <source>Int. J. Antimicrob. Agents</source>
  <year>2018</year>
  <volume>51</volume>
  <fpage>213</fpage>
  <lpage>220</lpage>
  <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.10.010</pub-id>
  <?supplied-pmid 29111434?>
  <pub-id pub-id-type="pmid">29111434</pub-id>
 </element-citation>
</ref>
